Pharmacokinetic Effect of Y-3 for Injection on Rosuvastatin Calcium Tablets in Healthy Participants

Exclusion criteria

• . People with allergies: allergies to medicines, food, pollen, etc., or those who have a history of allergy to rosuvastatin calcium tablet, Y-3 for injection or any of components of above investigational products;
• . Those who have diseases or medical history that may affect drug absorption, distribution, metabolism, excretion or interpretation of safety data, or diseases or medical history that can reduce compliance, including but not limited to gastrointestinal, renal, hepatic, pulmonary, neurological, hematological, endocrine, tumor, immunologic, psychiatric or cardiovascular and cerebrovascular diseases (especially liver and kidney insufficiency, diabetes, hypoglycemia, bleeding tendency or cachexia, malignant hypertension, thrombocytopenia);
• . Those who with myopathy, myalgia or rhabdomyolysis;
• . Those who have undergone surgery within 6 months prior to the first use of the investigational products, or who have undergone surgeries that may affect the absorption, distribution, metabolism, or excretion of the drug (such as cholecystectomy), or those who plan to undergo surgery during the trial;
• . Participants with a history of needle or blood phobia, intolerance to venipuncture or intravenous administration, or difficulty in blood sampling.
• . Those who cannot follow the uniform diet (e.g., special requirements for diet, intolerance to standard meals, hereditary galactose intolerance, lactase deficiency or glucose-galactose malabsorption).
• . For patients with creatinine clearance \<80 mL/min, creatinine clearance (mL/min) = \[(140-age) × body weight (kg)\]/\[72×Scr(mg/dl)\] or creatinine clearance (mL/min) = \[(140-age) × body weight(kg)\]/\[0.818×Scr(μmol/L)\], female study participants were × 0.85 according to the calculated results;
• . Those who have participated in or are participating in other clinical trials within 3 months before the first use of the investigational products (drug clinical trial is defined as the use of clinical investigational products), or planning to participate in other clinical trials during the trial period or within 1 month after the end of the trial, or those who do not come to participate in clinical trials in person;